Thermo Fisher Scientific Inc · NYSE:TMO
Thermo Fisher Scientific — Merger or Acquisition (May 2017)
11 slides from Thermo Fisher Scientific's merger presentation, May 15, 2017
Slide 1: Thermo Fisher to Acquire Patheon N.V.
May 15, 2017 Thermo Fisher to Acquire Patheon N.V. Exhibit 99.2
Slide 2: Safe Harbor Statement / Use of Non-GAAP Financial Measures
Safe Harbor Statement / Use of Non-GAAP Financial Measures The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements that involve a number of risks and uncertainties. Words such as “believes,
Slide 3: Tender offer notice and additional information
The tender offer referenced herein has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of Patheon or any other securities, nor is it a substitute for the tender offer materials tha
Slide 4: Acquisition of Patheon – Creating Customer & Shareholder Value
Acquisition of Patheon – Creating Customer & Shareholder Value Patheon – a leading Contract Development & Manufacturing Organization (CDMO) Excellent complementary capabilities that strengthen our unique value proposition for biopharma customers Net purchase price of $7.2B in cash, which includes th
Slide 5: CDMO: A Large and High-Growth Market
CDMO: A Large and High-Growth Market A $40B global market growing mid-single to high-single digits Biotech companies typically require a broad set of outsourced development and manufacturing capabilities Larger biopharma players are increasing outsourcing and consolidating to fewer, trusted supplier
Slide 6: Patheon Overview
Patheon Overview Locations St. Louis, MO Manati, Puerto Rico Florence, SC Greenville, NC Linz, Austria Ferentino and Monza, Italy Drug Product Services Drug Substance Services - Biologics Drug Substance Services - API Pharma Development Services 4% 28% 68% Europe North America ROW Revenue by Geograp
Slide 7: Strategic Rationale for Acquisition of Patheon
Strategic Rationale for Acquisition of Patheon Provides entry into the attractive, high-growth, fragmented CDMO market Enhances Thermo Fisher Scientific’s unique customer value proposition for biopharma customers Thermo Fisher’s unmatched global commercial reach opens new opportunities for Patheon D
Slide 8: Complementary Offerings Create Significant Customer Benefits
Complementary Offerings Create Significant Customer Benefits Leading positions in: Cell culture media Single-use technologies Control systems and software Biologics development and manufacturing capability and expertise Leading clinical trials packaging, distribution and logistics provider Formulati
Slide 9: Compelling Financial Profile
Compelling Financial Profile Price Total net cash consideration of $7.2B, which includes the assumption of $2.0B of net debt1 $35 per fully diluted share Returns Attractive return profile and accretive to adjusted EPS Expected to add $0.30 to adjusted EPS in first full year after close Synergies Est
Slide 10: Transaction Overview
Transaction Overview Financing Fully committed bridge facility in place Permanent financing from issuance of new debt plus approximately $2B of new equity Leverage Pro forma leverage ratio expected to be approximately 4x at close Our strong free cash flow will allow for rapid repayment of debt Path
Slide 11: Acquisition of Patheon – Creating Customer & Shareholder Value
Acquisition of Patheon – Creating Customer & Shareholder Value Patheon – a leading Contract Development & Manufacturing Organization (CDMO) Excellent complementary capabilities that strengthen our unique value proposition for biopharma customers Net purchase price of $7.2B in cash, which includes th
Thermo Fisher Scientific — Merger or Acquisition (May 2017) on 6ix